img

Global CD47 (IAP) Market Insights, Forecast to 2034

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global CD47 (IAP) Market Insights, Forecast to 2034

Market Analysis and InsightsGlobal CD47 (IAP) Market
Global CD47 (IAP) market is expected to reach to US$ million in 2024, with a positive growth of %, compared with US$ million in 2022. Backed with the increasing demand from downstream industries, CD47 (IAP) industry is evaluated to reach US$ million in 2029. The CAGR will be % during 2024 to 2029.
Globally, CD47 (IAP) key companies include Gilead, Innovent Biologics, Akeso, Inc, Arch Oncology, ImmuneOncia Therapeutics, I-MAB, Sorrento Therapeutics, Zai Lab and ImmuneOnco, etc. Gilead, Innovent Biologics, Akeso, Inc are top 3 players and held % share in total in 2022.
When considering the consumption regions, % revenue of CD47 (IAP) were sold to North America, Europe and Asia Pacific in 2022. Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2029 and the share will be % in 2029. Moreover, China, plays a key role in the whole CD47 (IAP) market and estimated to attract more attentions from industry insiders and investors.
CD47 (IAP) can be divided into CD47 Monoclonal Antibody, CD47 Double Antibody and CD47 Fusion Protein,, etc. CD47 Monoclonal Antibody is the mainstream product in the market, accounting for % revenue share globally in 2022 and the proportion will be % in 2029.
CD47 (IAP) is widely used in various fields, such as Solid Tumor, Lymphoma and Others,, etc. Solid Tumor provides greatest supports to the CD47 (IAP) industry development. In 2022, global % revenue of CD47 (IAP) went into Solid Tumor filed and the proportion will reach to % in 2029.
Report Covers
This report presents an overview of global CD47 (IAP) market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global CD47 (IAP) market with multiple angles. Items like regional revenue from 2018 to 2029 and companies’ revenue and gross margin from 2018 to 2024 are analyzed. In addition, revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Companies, Type, Application and Regions Listed in the Report



By Company


Gilead
Innovent Biologics
Akeso, Inc
Arch Oncology
ImmuneOncia Therapeutics
I-MAB
Sorrento Therapeutics
Zai Lab
ImmuneOnco
Hengrui
Beijing Mab-works
Hanxbio
ALX Oncology
Surface Oncology
TG Therapeutics
EpicentRx
Segment by Type
CD47 Monoclonal Antibody
CD47 Double Antibody
CD47 Fusion Protein

Segment by Application


Solid Tumor
Lymphoma
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue analysis from 2018 to 2029
Chapter 3Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Product revenue analysis by type from 2018 to 2029 globally
Chapter 5Product revenue analysis by application from 2018 to 2029 globally
Chapter 6Product revenue analysis by type and application from 2018 to 2029 in US & Canada. Product revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product revenue analysis by type and application from 2018 to 2029 in Europe. Product revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product revenue analysis by type and application from 2018 to 2029 in China. Product revenue analysis of China from 2018 to 2029
Chapter 9Product revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Companies’ outline, covering company’s basic information, major business, CD47 (IAP) introduction, etc. CD47 (IAP) Revenue and Gross Margin of each company from 2018 to 2024
Chapter 12Mr Accuracy reports Conclusions of CD47 (IAP)
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports

Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global CD47 (IAP) Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 CD47 Monoclonal Antibody
1.2.3 CD47 Double Antibody
1.2.4 CD47 Fusion Protein
1.3 Market by Application
1.3.1 Global CD47 (IAP) Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Solid Tumor
1.3.3 Lymphoma
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global CD47 (IAP) Market Perspective (2018-2029)
2.2 Global CD47 (IAP) Growth Trends by Region
2.2.1 CD47 (IAP) Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 CD47 (IAP) Historic Market Size by Region (2018-2024)
2.2.3 CD47 (IAP) Forecasted Market Size by Region (2024-2029)
2.3 CD47 (IAP) Market Dynamics
2.3.1 CD47 (IAP) Industry Trends
2.3.2 CD47 (IAP) Market Drivers
2.3.3 CD47 (IAP) Market Challenges
2.3.4 CD47 (IAP) Market Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue CD47 (IAP) by Players
3.1.1 Global CD47 (IAP) Revenue by Players (2018-2024)
3.1.2 Global CD47 (IAP) Revenue Market Share by Players (2018-2024)
3.2 Global CD47 (IAP) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of CD47 (IAP), Ranking by Revenue, 2021 VS 2022 VS 2024
3.4 Global CD47 (IAP) Market Concentration Ratio
3.4.1 Global CD47 (IAP) Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by CD47 (IAP) Revenue in 2022
3.5 Global Key Players of CD47 (IAP) Head office and Area Served
3.6 Global Key Players of CD47 (IAP), Product and Application
3.7 Global Key Players of CD47 (IAP), Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 CD47 (IAP) Breakdown Data by Type
4.1 Global CD47 (IAP) Historic Market Size by Type (2018-2024)
4.2 Global CD47 (IAP) Forecasted Market Size by Type (2024-2029)
5 CD47 (IAP) Breakdown Data by Application
5.1 Global CD47 (IAP) Historic Market Size by Application (2018-2024)
5.2 Global CD47 (IAP) Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America CD47 (IAP) Market Size (2018-2029)
6.2 North America CD47 (IAP) Market Size by Type
6.2.1 North America CD47 (IAP) Market Size by Type (2018-2024)
6.2.2 North America CD47 (IAP) Market Size by Type (2024-2029)
6.2.3 North America CD47 (IAP) Market Share by Type (2018-2029)
6.3 North America CD47 (IAP) Market Size by Application
6.3.1 North America CD47 (IAP) Market Size by Application (2018-2024)
6.3.2 North America CD47 (IAP) Market Size by Application (2024-2029)
6.3.3 North America CD47 (IAP) Market Share by Application (2018-2029)
6.4 North America CD47 (IAP) Market Size by Country
6.4.1 North America CD47 (IAP) Market Size by Country: 2018 VS 2022 VS 2029
6.4.2 North America CD47 (IAP) Market Size by Country (2018-2024)
6.4.3 North America CD47 (IAP) Market Size by Country (2024-2029)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe CD47 (IAP) Market Size (2018-2029)
7.2 Europe CD47 (IAP) Market Size by Type
7.2.1 Europe CD47 (IAP) Market Size by Type (2018-2024)
7.2.2 Europe CD47 (IAP) Market Size by Type (2024-2029)
7.2.3 Europe CD47 (IAP) Market Share by Type (2018-2029)
7.3 Europe CD47 (IAP) Market Size by Application
7.3.1 Europe CD47 (IAP) Market Size by Application (2018-2024)
7.3.2 Europe CD47 (IAP) Market Size by Application (2024-2029)
7.3.3 Europe CD47 (IAP) Market Share by Application (2018-2029)
7.4 Europe CD47 (IAP) Market Size by Country
7.4.1 Europe CD47 (IAP) Market Size by Country: 2018 VS 2022 VS 2029
7.4.2 Europe CD47 (IAP) Market Size by Country (2018-2024)
7.4.3 Europe CD47 (IAP) Market Size by Country (2024-2029)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China CD47 (IAP) Market Size (2018-2029)
8.2 China CD47 (IAP) Market Size by Type
8.2.1 China CD47 (IAP) Market Size by Type (2018-2024)
8.2.2 China CD47 (IAP) Market Size by Type (2024-2029)
8.2.3 China CD47 (IAP) Market Share by Type (2018-2029)
8.3 China CD47 (IAP) Market Size by Application
8.3.1 China CD47 (IAP) Market Size by Application (2018-2024)
8.3.2 China CD47 (IAP) Market Size by Application (2024-2029)
8.3.3 China CD47 (IAP) Market Share by Application (2018-2029)
9 Asia (excluding China)
9.1 Asia CD47 (IAP) Market Size (2018-2029)
9.2 Asia CD47 (IAP) Market Size by Type
9.2.1 Asia CD47 (IAP) Market Size by Type (2018-2024)
9.2.2 Asia CD47 (IAP) Market Size by Type (2024-2029)
9.2.3 Asia CD47 (IAP) Market Share by Type (2018-2029)
9.3 Asia CD47 (IAP) Market Size by Application
9.3.1 Asia CD47 (IAP) Market Size by Application (2018-2024)
9.3.2 Asia CD47 (IAP) Market Size by Application (2024-2029)
9.3.3 Asia CD47 (IAP) Market Share by Application (2018-2029)
9.4 Asia CD47 (IAP) Market Size by Region
9.4.1 Asia CD47 (IAP) Market Size by Region: 2018 VS 2022 VS 2029
9.4.2 Asia CD47 (IAP) Market Size by Region (2018-2024)
9.4.3 Asia CD47 (IAP) Market Size by Region (2024-2029)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America CD47 (IAP) Market Size (2018-2029)
10.2 Middle East, Africa, and Latin America CD47 (IAP) Market Size by Type
10.2.1 Middle East, Africa, and Latin America CD47 (IAP) Market Size by Type (2018-2024)
10.2.2 Middle East, Africa, and Latin America CD47 (IAP) Market Size by Type (2024-2029)
10.2.3 Middle East, Africa, and Latin America CD47 (IAP) Market Share by Type (2018-2029)
10.3 Middle East, Africa, and Latin America CD47 (IAP) Market Size by Application
10.3.1 Middle East, Africa, and Latin America CD47 (IAP) Market Size by Application (2018-2024)
10.3.2 Middle East, Africa, and Latin America CD47 (IAP) Market Size by Application (2024-2029)
10.3.3 Middle East, Africa, and Latin America CD47 (IAP) Market Share by Application (2018-2029)
10.4 Middle East, Africa, and Latin America CD47 (IAP) Market Size by Country
10.4.1 Middle East, Africa, and Latin America CD47 (IAP) Market Size by Country: 2018 VS 2022 VS 2029
10.4.2 Middle East, Africa, and Latin America CD47 (IAP) Market Size by Country (2018-2024)
10.4.3 Middle East, Africa, and Latin America CD47 (IAP) Market Size by Country (2024-2029)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 Gilead
11.1.1 Gilead Company Details
11.1.2 Gilead Business Overview
11.1.3 Gilead CD47 (IAP) Introduction
11.1.4 Gilead Revenue in CD47 (IAP) Business (2018-2024)
11.1.5 Gilead Recent Developments
11.2 Innovent Biologics
11.2.1 Innovent Biologics Company Details
11.2.2 Innovent Biologics Business Overview
11.2.3 Innovent Biologics CD47 (IAP) Introduction
11.2.4 Innovent Biologics Revenue in CD47 (IAP) Business (2018-2024)
11.2.5 Innovent Biologics Recent Developments
11.3 Akeso, Inc
11.3.1 Akeso, Inc Company Details
11.3.2 Akeso, Inc Business Overview
11.3.3 Akeso, Inc CD47 (IAP) Introduction
11.3.4 Akeso, Inc Revenue in CD47 (IAP) Business (2018-2024)
11.3.5 Akeso, Inc Recent Developments
11.4 Arch Oncology
11.4.1 Arch Oncology Company Details
11.4.2 Arch Oncology Business Overview
11.4.3 Arch Oncology CD47 (IAP) Introduction
11.4.4 Arch Oncology Revenue in CD47 (IAP) Business (2018-2024)
11.4.5 Arch Oncology Recent Developments
11.5 ImmuneOncia Therapeutics
11.5.1 ImmuneOncia Therapeutics Company Details
11.5.2 ImmuneOncia Therapeutics Business Overview
11.5.3 ImmuneOncia Therapeutics CD47 (IAP) Introduction
11.5.4 ImmuneOncia Therapeutics Revenue in CD47 (IAP) Business (2018-2024)
11.5.5 ImmuneOncia Therapeutics Recent Developments
11.6 I-MAB
11.6.1 I-MAB Company Details
11.6.2 I-MAB Business Overview
11.6.3 I-MAB CD47 (IAP) Introduction
11.6.4 I-MAB Revenue in CD47 (IAP) Business (2018-2024)
11.6.5 I-MAB Recent Developments
11.7 Sorrento Therapeutics
11.7.1 Sorrento Therapeutics Company Details
11.7.2 Sorrento Therapeutics Business Overview
11.7.3 Sorrento Therapeutics CD47 (IAP) Introduction
11.7.4 Sorrento Therapeutics Revenue in CD47 (IAP) Business (2018-2024)
11.7.5 Sorrento Therapeutics Recent Developments
11.8 Zai Lab
11.8.1 Zai Lab Company Details
11.8.2 Zai Lab Business Overview
11.8.3 Zai Lab CD47 (IAP) Introduction
11.8.4 Zai Lab Revenue in CD47 (IAP) Business (2018-2024)
11.8.5 Zai Lab Recent Developments
11.9 ImmuneOnco
11.9.1 ImmuneOnco Company Details
11.9.2 ImmuneOnco Business Overview
11.9.3 ImmuneOnco CD47 (IAP) Introduction
11.9.4 ImmuneOnco Revenue in CD47 (IAP) Business (2018-2024)
11.9.5 ImmuneOnco Recent Developments
11.10 Hengrui
11.10.1 Hengrui Company Details
11.10.2 Hengrui Business Overview
11.10.3 Hengrui CD47 (IAP) Introduction
11.10.4 Hengrui Revenue in CD47 (IAP) Business (2018-2024)
11.10.5 Hengrui Recent Developments
11.11 Beijing Mab-works
11.11.1 Beijing Mab-works Company Details
11.11.2 Beijing Mab-works Business Overview
11.11.3 Beijing Mab-works CD47 (IAP) Introduction
11.11.4 Beijing Mab-works Revenue in CD47 (IAP) Business (2018-2024)
11.11.5 Beijing Mab-works Recent Developments
11.12 Hanxbio
11.12.1 Hanxbio Company Details
11.12.2 Hanxbio Business Overview
11.12.3 Hanxbio CD47 (IAP) Introduction
11.12.4 Hanxbio Revenue in CD47 (IAP) Business (2018-2024)
11.12.5 Hanxbio Recent Developments
11.13 ALX Oncology
11.13.1 ALX Oncology Company Details
11.13.2 ALX Oncology Business Overview
11.13.3 ALX Oncology CD47 (IAP) Introduction
11.13.4 ALX Oncology Revenue in CD47 (IAP) Business (2018-2024)
11.13.5 ALX Oncology Recent Developments
11.14 Surface Oncology
11.14.1 Surface Oncology Company Details
11.14.2 Surface Oncology Business Overview
11.14.3 Surface Oncology CD47 (IAP) Introduction
11.14.4 Surface Oncology Revenue in CD47 (IAP) Business (2018-2024)
11.14.5 Surface Oncology Recent Developments
11.15 TG Therapeutics
11.15.1 TG Therapeutics Company Details
11.15.2 TG Therapeutics Business Overview
11.15.3 TG Therapeutics CD47 (IAP) Introduction
11.15.4 TG Therapeutics Revenue in CD47 (IAP) Business (2018-2024)
11.15.5 TG Therapeutics Recent Developments
11.16 EpicentRx
11.16.1 EpicentRx Company Details
11.16.2 EpicentRx Business Overview
11.16.3 EpicentRx CD47 (IAP) Introduction
11.16.4 EpicentRx Revenue in CD47 (IAP) Business (2018-2024)
11.16.5 EpicentRx Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Figure

List of Tables
Table 1. Global CD47 (IAP) Market Size Growth Rate by Type (US$ Million), 2018 VS 2022 VS 2029
Table 2. Key Players of CD47 Monoclonal Antibody
Table 3. Key Players of CD47 Double Antibody
Table 4. Key Players of CD47 Fusion Protein
Table 5. Global CD47 (IAP) Market Size Growth Rate by Application (US$ Million), 2018 VS 2022 VS 2029
Table 6. Global CD47 (IAP) Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
Table 7. Global CD47 (IAP) Market Size by Region (2018-2024) & (US$ Million)
Table 8. Global CD47 (IAP) Market Share by Region (2018-2024)
Table 9. Global CD47 (IAP) Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 10. Global CD47 (IAP) Market Share by Region (2024-2029)
Table 11. CD47 (IAP) Market Trends
Table 12. CD47 (IAP) Market Drivers
Table 13. CD47 (IAP) Market Challenges
Table 14. CD47 (IAP) Market Restraints
Table 15. Global CD47 (IAP) Revenue by Players (2018-2024) & (US$ Million)
Table 16. Global CD47 (IAP) Revenue Share by Players (2018-2024)
Table 17. Global Top CD47 (IAP) by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in CD47 (IAP) as of 2022)
Table 18. Global CD47 (IAP) Industry Ranking 2021 VS 2022 VS 2024
Table 19. Global 5 Largest Players Market Share by CD47 (IAP) Revenue (CR5 and HHI) & (2018-2024)
Table 20. Global Key Players of CD47 (IAP), Headquarters and Area Served
Table 21. Global Key Players of CD47 (IAP), Product and Application
Table 22. Global Key Players of CD47 (IAP), Product and Application
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global CD47 (IAP) Market Size by Type (2018-2024) & (US$ Million)
Table 25. Global CD47 (IAP) Revenue Market Share by Type (2018-2024)
Table 26. Global CD47 (IAP) Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 27. Global CD47 (IAP) Revenue Market Share by Type (2024-2029)
Table 28. Global CD47 (IAP) Market Size by Application (2018-2024) & (US$ Million)
Table 29. Global CD47 (IAP) Revenue Share by Application (2018-2024)
Table 30. Global CD47 (IAP) Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 31. Global CD47 (IAP) Revenue Share by Application (2024-2029)
Table 32. North America CD47 (IAP) Market Size by Type (2018-2024) & (US$ Million)
Table 33. North America CD47 (IAP) Market Size by Type (2024-2029) & (US$ Million)
Table 34. North America CD47 (IAP) Market Size by Application (2018-2024) & (US$ Million)
Table 35. North America CD47 (IAP) Market Size by Application (2024-2029) & (US$ Million)
Table 36. North America CD47 (IAP) Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 37. North America CD47 (IAP) Market Size by Country (2018-2024) & (US$ Million)
Table 38. North America CD47 (IAP) Market Size by Country (2024-2029) & (US$ Million)
Table 39. Europe CD47 (IAP) Market Size by Type (2018-2024) & (US$ Million)
Table 40. Europe CD47 (IAP) Market Size by Type (2024-2029) & (US$ Million)
Table 41. Europe CD47 (IAP) Market Size by Application (2018-2024) & (US$ Million)
Table 42. Europe CD47 (IAP) Market Size by Application (2024-2029) & (US$ Million)
Table 43. Europe CD47 (IAP) Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 44. Europe CD47 (IAP) Market Size by Country (2018-2024) & (US$ Million)
Table 45. Europe CD47 (IAP) Market Size by Country (2024-2029) & (US$ Million)
Table 46. China CD47 (IAP) Market Size by Type (2018-2024) & (US$ Million)
Table 47. China CD47 (IAP) Market Size by Type (2024-2029) & (US$ Million)
Table 48. China CD47 (IAP) Market Size by Application (2018-2024) & (US$ Million)
Table 49. China CD47 (IAP) Market Size by Application (2024-2029) & (US$ Million)
Table 50. Asia CD47 (IAP) Market Size by Type (2018-2024) & (US$ Million)
Table 51. Asia CD47 (IAP) Market Size by Type (2024-2029) & (US$ Million)
Table 52. Asia CD47 (IAP) Market Size by Application (2018-2024) & (US$ Million)
Table 53. Asia CD47 (IAP) Market Size by Application (2024-2029) & (US$ Million)
Table 54. Asia CD47 (IAP) Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
Table 55. Asia CD47 (IAP) Market Size by Region (2018-2024) & (US$ Million)
Table 56. Asia CD47 (IAP) Market Size by Region (2024-2029) & (US$ Million)
Table 57. Middle East, Africa, and Latin America CD47 (IAP) Market Size by Type (2018-2024) & (US$ Million)
Table 58. Middle East, Africa, and Latin America CD47 (IAP) Market Size by Type (2024-2029) & (US$ Million)
Table 59. Middle East, Africa, and Latin America CD47 (IAP) Market Size by Application (2018-2024) & (US$ Million)
Table 60. Middle East, Africa, and Latin America CD47 (IAP) Market Size by Application (2024-2029) & (US$ Million)
Table 61. Middle East, Africa, and Latin America CD47 (IAP) Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 62. Middle East, Africa, and Latin America CD47 (IAP) Market Size by Country (2018-2024) & (US$ Million)
Table 63. Middle East, Africa, and Latin America CD47 (IAP) Market Size by Country (2024-2029) & (US$ Million)
Table 64. Gilead Company Details
Table 65. Gilead Business Overview
Table 66. Gilead CD47 (IAP) Product
Table 67. Gilead Revenue in CD47 (IAP) Business (2018-2024) & (US$ Million)
Table 68. Gilead Recent Developments
Table 69. Innovent Biologics Company Details
Table 70. Innovent Biologics Business Overview
Table 71. Innovent Biologics CD47 (IAP) Product
Table 72. Innovent Biologics Revenue in CD47 (IAP) Business (2018-2024) & (US$ Million)
Table 73. Innovent Biologics Recent Developments
Table 74. Akeso, Inc Company Details
Table 75. Akeso, Inc Business Overview
Table 76. Akeso, Inc CD47 (IAP) Product
Table 77. Akeso, Inc Revenue in CD47 (IAP) Business (2018-2024) & (US$ Million)
Table 78. Akeso, Inc Recent Developments
Table 79. Arch Oncology Company Details
Table 80. Arch Oncology Business Overview
Table 81. Arch Oncology CD47 (IAP) Product
Table 82. Arch Oncology Revenue in CD47 (IAP) Business (2018-2024) & (US$ Million)
Table 83. Arch Oncology Recent Developments
Table 84. ImmuneOncia Therapeutics Company Details
Table 85. ImmuneOncia Therapeutics Business Overview
Table 86. ImmuneOncia Therapeutics CD47 (IAP) Product
Table 87. ImmuneOncia Therapeutics Revenue in CD47 (IAP) Business (2018-2024) & (US$ Million)
Table 88. ImmuneOncia Therapeutics Recent Developments
Table 89. I-MAB Company Details
Table 90. I-MAB Business Overview
Table 91. I-MAB CD47 (IAP) Product
Table 92. I-MAB Revenue in CD47 (IAP) Business (2018-2024) & (US$ Million)
Table 93. I-MAB Recent Developments
Table 94. Sorrento Therapeutics Company Details
Table 95. Sorrento Therapeutics Business Overview
Table 96. Sorrento Therapeutics CD47 (IAP) Product
Table 97. Sorrento Therapeutics Revenue in CD47 (IAP) Business (2018-2024) & (US$ Million)
Table 98. Sorrento Therapeutics Recent Developments
Table 99. Zai Lab Company Details
Table 100. Zai Lab Business Overview
Table 101. Zai Lab CD47 (IAP) Product
Table 102. Zai Lab Revenue in CD47 (IAP) Business (2018-2024) & (US$ Million)
Table 103. Zai Lab Recent Developments
Table 104. ImmuneOnco Company Details
Table 105. ImmuneOnco Business Overview
Table 106. ImmuneOnco CD47 (IAP) Product
Table 107. ImmuneOnco Revenue in CD47 (IAP) Business (2018-2024) & (US$ Million)
Table 108. ImmuneOnco Recent Developments
Table 109. Hengrui Company Details
Table 110. Hengrui Business Overview
Table 111. Hengrui CD47 (IAP) Product
Table 112. Hengrui Revenue in CD47 (IAP) Business (2018-2024) & (US$ Million)
Table 113. Hengrui Recent Developments
Table 114. Beijing Mab-works Company Details
Table 115. Beijing Mab-works Business Overview
Table 116. Beijing Mab-works CD47 (IAP) Product
Table 117. Beijing Mab-works Revenue in CD47 (IAP) Business (2018-2024) & (US$ Million)
Table 118. Beijing Mab-works Recent Developments
Table 119. Hanxbio Company Details
Table 120. Hanxbio Business Overview
Table 121. Hanxbio CD47 (IAP) Product
Table 122. Hanxbio Revenue in CD47 (IAP) Business (2018-2024) & (US$ Million)
Table 123. Hanxbio Recent Developments
Table 124. ALX Oncology Company Details
Table 125. ALX Oncology Business Overview
Table 126. ALX Oncology CD47 (IAP) Product
Table 127. ALX Oncology Revenue in CD47 (IAP) Business (2018-2024) & (US$ Million)
Table 128. ALX Oncology Recent Developments
Table 129. Surface Oncology Company Details
Table 130. Surface Oncology Business Overview
Table 131. Surface Oncology CD47 (IAP) Product
Table 132. Surface Oncology Revenue in CD47 (IAP) Business (2018-2024) & (US$ Million)
Table 133. Surface Oncology Recent Developments
Table 134. TG Therapeutics Company Details
Table 135. TG Therapeutics Business Overview
Table 136. TG Therapeutics CD47 (IAP) Product
Table 137. TG Therapeutics Revenue in CD47 (IAP) Business (2018-2024) & (US$ Million)
Table 138. TG Therapeutics Recent Developments
Table 139. EpicentRx Company Details
Table 140. EpicentRx Business Overview
Table 141. EpicentRx CD47 (IAP) Product
Table 142. EpicentRx Revenue in CD47 (IAP) Business (2018-2024) & (US$ Million)
Table 143. EpicentRx Recent Developments
Table 144. Research Programs/Design for This Report
Table 145. Key Data Information from Secondary Sources
Table 146. Key Data Information from Primary Sources
List of Figures
Figure 1. Global CD47 (IAP) Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Figure 2. Global CD47 (IAP) Market Share by Type: 2022 VS 2029
Figure 3. CD47 Monoclonal Antibody Features
Figure 4. CD47 Double Antibody Features
Figure 5. CD47 Fusion Protein Features
Figure 6. Global CD47 (IAP) Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Figure 7. Global CD47 (IAP) Market Share by Application: 2022 VS 2029
Figure 8. Solid Tumor Case Studies
Figure 9. Lymphoma Case Studies
Figure 10. Others Case Studies
Figure 11. CD47 (IAP) Report Years Considered
Figure 12. Global CD47 (IAP) Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 13. Global CD47 (IAP) Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 14. Global CD47 (IAP) Market Share by Region: 2022 VS 2029
Figure 15. Global CD47 (IAP) Market Share by Players in 2022
Figure 16. Global Top CD47 (IAP) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in CD47 (IAP) as of 2022)
Figure 17. The Top 10 and 5 Players Market Share by CD47 (IAP) Revenue in 2022
Figure 18. North America CD47 (IAP) Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 19. North America CD47 (IAP) Market Share by Type (2018-2029)
Figure 20. North America CD47 (IAP) Market Share by Application (2018-2029)
Figure 21. North America CD47 (IAP) Market Share by Country (2018-2029)
Figure 22. United States CD47 (IAP) Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 23. Canada CD47 (IAP) Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 24. Europe CD47 (IAP) Market Size YoY (2018-2029) & (US$ Million)
Figure 25. Europe CD47 (IAP) Market Share by Type (2018-2029)
Figure 26. Europe CD47 (IAP) Market Share by Application (2018-2029)
Figure 27. Europe CD47 (IAP) Market Share by Country (2018-2029)
Figure 28. Germany CD47 (IAP) Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 29. France CD47 (IAP) Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 30. U.K. CD47 (IAP) Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 31. Italy CD47 (IAP) Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 32. Russia CD47 (IAP) Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 33. Nordic Countries CD47 (IAP) Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 34. China CD47 (IAP) Market Size YoY (2018-2029) & (US$ Million)
Figure 35. China CD47 (IAP) Market Share by Type (2018-2029)
Figure 36. China CD47 (IAP) Market Share by Application (2018-2029)
Figure 37. Asia CD47 (IAP) Market Size YoY (2018-2029) & (US$ Million)
Figure 38. Asia CD47 (IAP) Market Share by Type (2018-2029)
Figure 39. Asia CD47 (IAP) Market Share by Application (2018-2029)
Figure 40. Asia CD47 (IAP) Market Share by Region (2018-2029)
Figure 41. Japan CD47 (IAP) Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 42. South Korea CD47 (IAP) Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 43. China Taiwan CD47 (IAP) Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 44. Southeast Asia CD47 (IAP) Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 45. India CD47 (IAP) Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 46. Australia CD47 (IAP) Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 47. Middle East, Africa, and Latin America CD47 (IAP) Market Size YoY (2018-2029) & (US$ Million)
Figure 48. Middle East, Africa, and Latin America CD47 (IAP) Market Share by Type (2018-2029)
Figure 49. Middle East, Africa, and Latin America CD47 (IAP) Market Share by Application (2018-2029)
Figure 50. Middle East, Africa, and Latin America CD47 (IAP) Market Share by Country (2018-2029)
Figure 51. Brazil CD47 (IAP) Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 52. Mexico CD47 (IAP) Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 53. Turkey CD47 (IAP) Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 54. Saudi Arabia CD47 (IAP) Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 55. Israel CD47 (IAP) Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 56. GCC Countries CD47 (IAP) Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 57. Gilead Revenue Growth Rate in CD47 (IAP) Business (2018-2024)
Figure 58. Innovent Biologics Revenue Growth Rate in CD47 (IAP) Business (2018-2024)
Figure 59. Akeso, Inc Revenue Growth Rate in CD47 (IAP) Business (2018-2024)
Figure 60. Arch Oncology Revenue Growth Rate in CD47 (IAP) Business (2018-2024)
Figure 61. ImmuneOncia Therapeutics Revenue Growth Rate in CD47 (IAP) Business (2018-2024)
Figure 62. I-MAB Revenue Growth Rate in CD47 (IAP) Business (2018-2024)
Figure 63. Sorrento Therapeutics Revenue Growth Rate in CD47 (IAP) Business (2018-2024)
Figure 64. Zai Lab Revenue Growth Rate in CD47 (IAP) Business (2018-2024)
Figure 65. ImmuneOnco Revenue Growth Rate in CD47 (IAP) Business (2018-2024)
Figure 66. Hengrui Revenue Growth Rate in CD47 (IAP) Business (2018-2024)
Figure 67. Beijing Mab-works Revenue Growth Rate in CD47 (IAP) Business (2018-2024)
Figure 68. Hanxbio Revenue Growth Rate in CD47 (IAP) Business (2018-2024)
Figure 69. ALX Oncology Revenue Growth Rate in CD47 (IAP) Business (2018-2024)
Figure 70. Surface Oncology Revenue Growth Rate in CD47 (IAP) Business (2018-2024)
Figure 71. TG Therapeutics Revenue Growth Rate in CD47 (IAP) Business (2018-2024)
Figure 72. EpicentRx Revenue Growth Rate in CD47 (IAP) Business (2018-2024)
Figure 73. Bottom-up and Top-down Approaches for This Report
Figure 74. Data Triangulation
Figure 75. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries